6 results about "Phosphodiesterase-4" patented technology

The present invention provides a oxazole compound represented by Formula (1), or a salt thereof:wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(═O)— wherein Y1 is a group such as —C(═O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.

This invention relates to a phosphodiesterase 4 (PDE4) inhibitor composition, belonging to the field of pharmaceutical formulations. The composition comprises a PDE4 inhibitor, a suspending agent, and other pharmaceutically acceptable excipients. The PDE4 inhibitor composition prepared by this invention has advantages such as good taste, convenient administration, high patient acceptance, and greater flexibility in clinical application.

The invention relates to a medicament and a method for treating or preventing vascular diseases. Specifically, the invention relates to a method for treating or preventing vascular endothelial dysfunction related diseases by down-regulating phosphodiesterase 4, and application of a phosphodiesterase 4 inhibitor in preparation of drugs for treating or preventing vascular endothelial dysfunction related diseases.

Disclosed are indolone compounds having phosphodiesterase 4 inhibitory activity, the compounds being represented by Formula I, which can be used as phosphodiesterase 4 inhibitors in therapeutic or prophylactic drugs for Behcet's disease, atopic dermatitis, psoriasis, inflammatory bowel disease, chronic obstructive pulmonary disease, pulmonary fibrosis, and other inflammatory diseases.

Disclosed are methods for treating Jordan's syndrome in a subject in need thereof and methods of reducing at least one sign or symptom of Jordan's syndrome in a subject in need thereof. The methods comprise administering a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor to the subject. The PDE4 inhibitor may be BPN14770 and may be administered daily.

Provided herein are phosphodiesterase 4 (PDE4) inhibitors, e.g., a compound of Formula (I) or (II), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease, disorder, or condition associated with PDE4 malfunction.